Sabby Management’s Arcturus Therapeutics ARCT Stock Holding History

Sabby Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-443	Closed	-$651K	–	264
2016 Q4	$651K	Sell	443 -246	-36%	-$3.68K	0.04%	175
2016 Q3	$1.19M	Buy	689 +51	+8%	+$1.65K	0.04%	167
2016 Q2	$2.01M	Buy	638 +451	+241%	+$14.2K	0.1%	109
2016 Q1	$497K	Buy	187 +116	+163%	+$3.93K	0.02%	213
2015 Q4	$314K	Buy	+71	New	+$3.2K	0.02%	268
2014 Q4	–	Sell	-83	Closed	-$900K	–	246
2014 Q3	$900K	Buy	+83	New	+$10.8K	0.03%	156

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

DFPG Investments Sandy, Utah $1.28B AUM 27.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Sabby Management's ARCT Position: Q4 2019 in Review

Sabby Management sold out of Arcturus Therapeutics (ARCT) in Q4 2019, closing a stake of 124,843 shares — an estimated $1.28M sold.

Sabby Management first reported a position in ARCT in Q4 2013 and held it in 7 quarters. The position peaked at $2.28M in Q4 2013. 50 funds tracked by Wall St. Rank hold ARCT as of Q4 2019.

Sabby Management reported no remaining Arcturus Therapeutics position as of Q4 2019 after selling out during the quarter.
Sabby Management sold 124,843 Arcturus Therapeutics shares in Q4 2019, an estimated $1.28M.
Sabby Management first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 7 quarters.
Sabby Management's Arcturus Therapeutics position peaked at $2.28M in Q4 2013.
50 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2019.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.